Literature DB >> 22232486

Small dose of rituximab for graves orbitopathy: new insights into the mechanism of action.

Mario Salvi1, Guia Vannucchi, Nicola Currò, Martino Introna, Stefania Rossi, Paola Bonara, Danila Covelli, Davide Dazzi, Claudio Guastella, Lorenzo Pignataro, Roberto Ratiglia, Josée Golay, Paolo Beck-Peccoz.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22232486     DOI： 10.1001/archopthalmol.2011.1215

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN： 0003-9950


× No keyword cloud information.
  15 in total

1.  Rituximab therapy for refractory orbital inflammation: results of a phase 1/2, dose-ranging, randomized clinical trial.

Authors:  Eric B Suhler; Lyndell L Lim; Robert M Beardsley; Tracy R Giles; Sirichai Pasadhika; Shelly T Lee; Alexandre de Saint Sardos; Nicholas J Butler; Justine R Smith; James T Rosenbaum
Journal:  JAMA Ophthalmol       Date:  2014-05       Impact factor: 7.389

Review 2.  Rituximab in the Treatment of Thyroid Eye Disease: A Review.

Authors:  Rochella A Ostrowski; Melissa R Bussey; Yasmin Shayesteh; Walter M Jay
Journal:  Neuroophthalmology       Date:  2015-06-17

Review 3.  Immunohistochemical analysis of human orbital tissue in Graves' orbitopathy.

Authors:  Y P Hai; A C H Lee; L Frommer; T Diana; G J Kahaly
Journal:  J Endocrinol Invest       Date:  2019-09-19       Impact factor: 4.256

Review 4.  Thyroid eye disease: current and potential medical management.

Authors:  Jessica M Pouso-Diz; Jose M Abalo-Lojo; Francisco Gonzalez
Journal:  Int Ophthalmol       Date:  2020-01-09       Impact factor: 2.031

Review 5.  Rituximab for thyroid-associated ophthalmopathy.

Authors:  Swan Kang; Shirin Hamed Azzam; Neda Minakaran; Daniel G Ezra
Journal:  Cochrane Database Syst Rev       Date:  2022-06-16

6.  Efficacy of B-cell targeted therapy with rituximab in patients with active moderate to severe Graves' orbitopathy: a randomized controlled study.

Authors:  Mario Salvi; Guia Vannucchi; Nicola Currò; Irene Campi; Danila Covelli; Davide Dazzi; Simona Simonetta; Claudio Guastella; Lorenzo Pignataro; Sabrina Avignone; Paolo Beck-Peccoz
Journal:  J Clin Endocrinol Metab       Date:  2014-12-15       Impact factor: 5.958

7.  The 2016 European Thyroid Association/European Group on Graves' Orbitopathy Guidelines for the Management of Graves' Orbitopathy.

Authors:  Luigi Bartalena; Lelio Baldeschi; Kostas Boboridis; Anja Eckstein; George J Kahaly; Claudio Marcocci; Petros Perros; Mario Salvi; Wilmar M Wiersinga
Journal:  Eur Thyroid J       Date:  2016-03-02

8.  Advances in the management of thyroid eye disease.

Authors:  César A Briceño; Shivani Gupta; Raymond S Douglas
Journal:  Int Ophthalmol Clin       Date:  2013

9.  Intraorbital injection of rituximab versus high dose of systemic glucocorticoids in the treatment of thyroid-associated orbitopathy.

Authors:  Gustavo Savino; Erika Mandarà; Mariangela Gari; Remo Battendieri; Salvatore Maria Corsello; Alfredo Pontecorvi
Journal:  Endocrine       Date:  2014-06-01       Impact factor: 3.633

10.  Association of T and B Cells Infiltrating Orbital Tissues With Clinical Features of Graves Orbitopathy.

Authors:  Giovanna Rotondo Dottore; Liborio Torregrossa; Patrizio Caturegli; Ilaria Ionni; Angela Sframeli; Elena Sabini; Francesca Menconi; Paolo Piaggi; Stefano Sellari-Franceschini; Marco Nardi; Francesco Latrofa; Paolo Vitti; Claudio Marcocci; Fulvio Basolo; Michele Marinò
Journal:  JAMA Ophthalmol       Date:  2018-06-01       Impact factor: 7.389
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.